Platform for discovering and developing first-in-class antibody medicines
AbCellera is a leading antibody discovery company using single-cell screening and AI to identify binders from immune repertoires at high speed. It excels in rapid hit identification for traditional targets and has supported multiple clinical programs through partnerships. Unlike Abalone Bio's focus on functional activation of GPCRs via massive parallel activity assays and survival-linked yeast, AbCellera prioritizes binding affinity and structural characterization with smaller functional follow-up. Its platform suits high-throughput discovery but lacks Abalone Bio's 100M-scale activity datasets for training AI on activators, making it less ideal for hard-to-drug GPCR modulation where precise function is required over inhibition.
Free